Mechanisms ofra Tetmethylpyrazine in spinal cord injury: a narrative review Authors: Yu Jiang, Gang Liu, Huizhong Bai, Jiashu Yue, Bowen Deng, Feng Gao, Jinyu Li, Xiaohong Mu Published: 2026 ABSTRACT Spinal cord injury (SCI) is characterized by irreversible loss of motor and sensory function, imposing a substantial burden on patients and their families. Tetramethylpyrazine (TMP), a bioactive compound derived from traditional Chinese medicine, possesses a wide range of pharmacological activities and has demonstrated potential therapeutic effects in the treatment of SCI. Therefore, this article provides a comprehensive review of the mechanisms by which TMP promotes spinal cord repair. This review compiles a large body of in vitro, in vivo, and clinical studies, including a total of 86 publications documenting the effects of TMP on SCI. The results indicate that the mechanisms by which TMP exerts its effects in SCI treatment include promoting nerve regeneration, improving vascular dysfunction, exerting anti-inflammatory effects, inhibiting neuronal apoptosis, reducing oxidative stress, regulating iron metabolism, maintaining ion homeostasis, alleviating pyroptosis, and modulating autophagy. Through these mechanisms, TMP contributes to the restoration of spinal cord morphology, motor function, and electrophysiological parameters in experimental animal models. Clinical reports on the use of TMP injection for SCI are relatively limited, and its clinical efficacy requires further investigation. The combined application of nanotechnology or hydrogels provides an efficient targeted delivery and sustained-release system for TMP in the spinal cord, thereby significantly enhancing its bioavailability. Overall, TMP shows promising potential in SCI treatment and may serve as a valuable adjunctive therapeutic strategy. Introduction Patients with spinal cord injury (SCI) frequently experience a range of neurological deficits, including partial or complete loss of sensory and motor functions below the level of injury. For instance, cervical spine injuries often result in quadriplegia, while thoracic spine injuries result in paraplegia, with severe cases potentially being life-threatening. Annually, approximately 930,000 new SCI cases are reported, and an estimated 27.04 million individuals are affected globally. SCI not only significantly impacts an individual’s quality of life but also imposes a considerable socioeconomic burden, with the estimated lifetime cost per person reaching approximately 2.35 million USD [1, 2]. Currently, clinical treatment options for SCI remain limited. Patient recovery primarily depends on surgical decompression and pharmacological interventions, and the ongoing search of more effective alternative therapies remains one of the key research focuses for this condition. Modern pharmacological studies have shown that the active components of traditional Chinese medicine exert their effects through multi-target and multi-pathway mechanisms, demonstrating significant therapeutic benefits in conditions like SCI. Among them, tetramethylpyrazine (TMP), an alkaloid derived from ligustrazine, has been shown to promote cell proliferation, inhibit apoptosis, induce vasodilation, regulate immune responses, exert anti-inflammatory and antioxidant effects, and enhance tissue microcirculation. TMP has been used in the treatment of cardiovascular and cerebrovascular diseases, including myocardial infarction, cerebral ischemia, brain injury, and Alzheimer’s disease. TMP also demonstrates neuroprotective effects in SCI and is increasingly regarded as a promising therapeutic candidate for this condition [3]. Meta-analyses have shown that TMP, the main active component of Ligusticum chuanxiong, is significantly more effective in reducing SCI-induced inflammation than other traditional Chinese medicines, such as Salvia miltiorrhiza (Danshen) [4]. This article provides a comprehensive review of the clinical applications, as well as in vivo and in vitro experimental studies, of TMP and its mechanisms of action in SCI repair. The aim is to present new therapeutic options for the clinical treatment of SCI. The main content of the article is summarized in Fig. 1. Fig. 1Graphical abstract. (The image was created using Photoshop) Graphical abstract. (The image was created using Photoshop) Materials and methods This was a narrative review. Sources of data The search strategy in this section was designed to be broad. Relevant data were obtained from both Chinese and English literature published before August 2025. These studies were sourced from PubMed, Springer, Web of Science, Cochrane, and China National Knowledge Infrastructure (CNKI). Boolean operators were used to combine search terms, specifically linking ‘SCI’ OR ‘spinal cord injury’ with ‘tetramethylpyrazine’ OR ‘TMP’ using the ‘AND’ operator to ensure a comprehensive collection of literature in both languages. Data selection Inclusion criteria Literature from the five databases was screened, with duplicates removed. Studies closely related to the research objectives and content of this paper were selected. The included studies had to focus on in vitro, in vivo, or clinical research on the use of TMP in the treatment of SCI. Exclusion criteria Non-Chinese and non-English literature; reviews, abstracts, conference papers, short reports, and newspaper articles; studies involving combination therapies or comprehensive treatment regimens where TMP’s independent contribution could not be demonstrated; articles lacking detailed research methods or with incomplete data or figures; and literature not aligned with the research objectives. The screening process is outlined in Fig. 2. Fig. 2Flow diagram for identifying eligible studies. (The image was created using Photoshop) Flow diagram for identifying eligible studies. (The image was created using Photoshop) Data extraction Two authors independently screened all included studies and performed data extraction. Discrepancies were resolved through consultation with a third author. Information such as authors, publication date, study design, animal species, disease modeling method, drug dosage, intervention duration, and outcome measures was extracted. Results of the review This section summarizes the findings from previously published in vivo and clinical studies evaluating TMP in SCI. The results are detailed below. Molecular structure of TMP Tetramethylpyrazine (TMP, C₈H₁₂N₂) is a bioactive monomer extracted from the traditional Chinese medicinal herb Chuanxiong. The chemical structure of TMP is shown in Fig. 3. TMP is an amide-type alkaloid with a pyrazine core substituted by four methyl groups. The unique molecular structure of TMP underlies its diverse pharmacological activities [5]. The pyrazine ring is a relatively planar, electron-deficient system that serves as the core pharmacophore, contributing to TMP’s broad therapeutic effects. ITMP exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties, and also regulates autophagy, angiogenesis, vasodilation, and endothelial function [6]. Additionally, the four highly symmetric methyl groups increase the molecule’s lipophilicity, allowing TMP to effectively penetrate the blood–brain barrier, making it a promising candidate for treating central nervous system diseases. Fig. 3Chemical structure of TMP. (The image was created using in Draw software) Chemical structure of TMP. (The image was created using in Draw software) Clinical application of TMP in SCI Currently, two salt forms of TMP have been approved for clinical use: TMP hydrochloride and TMP phosphate. TMP is a lipophilic alkaloid with poor water solubility. By combining TMP with hydrochloric acid or phosphoric acid, its water solubility and drug stability are significantly improved, enhancing its absorption and utilization in the human body, making it better suited for clinical application. In the treatment of SCI, TMP injection is typically diluted in 5% glucose injection or sodium chloride injection and administered via intravenous drip. Currently, there are limited reports on the use of TMP injection alone for SCI treatment, with only three studies available. Wu Xi administered TMP injection continuously for 14 days to 36 patients after SCI surgery. The motor and sensory function scores at 3, 6, and 12 months post-operation were all higher than those in the conventional treatment group, demonstrating that TMP can promote the recovery of motor and sensory function after SCI surgery, without any adverse effects on surgical recovery [7]. Du FT found that in patients with SCI, the high-dose group (240 mg) showed better postoperative motor scores and higher levels of TNF-α, IL-1β, Nrf2, GCLc, and GCLm in the cerebrospinal fluid compared to the low-dose group (120 mg) [8, 9]. herefore, it was concluded that TMP may promote SCI recovery by improving oxidative stress and inflammatory responses, with higher doses providing better therapeutic effects. The clinical study information is presented in Table 1. Although the above reports provide some evidence of the efficacy of TMP in promoting SCI recovery, and no adverse reactions have been reported so far, preliminary evidence suggests that TMP may be a beneficial adjunctive treatment option. Table 1Clinical application of TMP in SCIStudydesignDiseaseInterventionNumber of PatientTreatmentdurationResultsAdverseeffectscasecontrolcasecontrolDu2018RCTSCITMP(120/240 mg)Normal Saline603014d①TNF-α、IL-1β、Nrf2、GCLc、GCLm/Du2019RCTAfter surgery for acute SCITMP(240 mg)TMP(120 mg)454515d①Botsford score②FIM score③TNF-α、IL-1β/Wu2019RCTSCITMP(100 mg)Normal Saline363616d①Motor and Sensory Score/ Table 1Clinical application of TMP in SCIStudydesignDiseaseInterventionNumber of PatientTreatmentdurationResultsAdverseeffectscasecontrolcasecontrolDu2018RCTSCITMP(120/240 mg)Normal Saline603014d①TNF-α、IL-1β、Nrf2、GCLc、GCLm/Du2019RCTAfter surgery for acute SCITMP(240 mg)TMP(120 mg)454515d①Botsford score②FIM score③TNF-α、IL-1β/Wu2019RCTSCITMP(100 mg)Normal Saline363616d①Motor and Sensory Score/ Clinical application of TMP in SCI Du 2018 TMP (120/240 mg) Du 2019 TMP (240 mg) TMP (120 mg) Wu 2019 In vivo studies of TMP in SCI Rodents A total of 65 in vivo studies have investigated the effects of TMP using rodent models, including SD rats, C57BL/6 mice, and Wistar rats. The acute SCI model is primarily established through a modified Allen’s weight-drop method. One study employed balloon occlusion of the thoracic aorta to induce a spinal cord ischemia model. TMP is typically administered via intraperitoneal injection at a dose of 200 mg/kg [10]. The mechanisms through which TMP promotes SCI repair are multifaceted. These include enhancing neural repair, improving vascular dysfunction, exerting anti-inflammatory effects, inhibiting cell apoptosis, providing antioxidant benefits, improving iron metabolism, and regulating ion homeostasis. These mechanisms are interconnected and work synergistically at the molecular and cellular levels. Through multi-target and multi-pathway regulation, TMP ultimately facilitates both structural and functional repair of SCI at the tissue and functional levels. Promote nerve regeneration. Promote nerve regeneration. Promote nerve regeneration. Upregulation of neurotrophic factors Nerve growth factor (NGF) is a neuroprotective substance produced by neurons, glial cells, and others in the damaged spinal cord through autocrine and paracrine mechanisms. Brain-derived neurotrophic factor (BDNF) is an essential neurotrophic factor for maintaining neuronal survival, promoting neuronal differentiation, and supporting myelination. Zhou Y found that TMP can upregulate the expression of NGF and BDNF in the injured segment of the spinal cord [11]. Wang GQ found that TMP promotes the upregulation of CAP-43 expression after SCI, which is also an important growth protein related to neural development and repair [12]. Yang F found that TMP can also promote the expression of neurotrophic factor NT-4 and TrkA after acute SCI [13]. TrkA is a high-affinity receptor for neurotrophic factors, and neurotrophic factors must bind to this receptor to initiate cellular signaling pathways and exert their biological effects. Reduction of glial scars The formation of glial scars is considered a major obstacle to axonal regeneration. The proliferation and hypertrophy of astrocytes (AS) is one of the factors that contribute to the formation of glial scars [14].In the inflammatory response, the key enzyme cytosolic phospholipase A2 (cPLA2) can hydrolyze membrane phospholipids to release arachidonic acid, thereby promoting the occurrence of the inflammatory cascade, activating astrocytes, and facilitating glial scar formation. Glial fibrillary acidic protein (GFAP), as a cytoskeletal protein of astrocytes, is a marker of astrocyte activation. Chen X found that after TMP intervention, the positive area expression of GFAP and cPLA2 started to be lower than the model group on the third day. Furthermore, 21 days after SCI, HE staining showed that the model group had already developed glial scars, while the TMP group only exhibited ischemic changes. TMP effectively inhibited the excessive hypertrophy of activated astrocytes and delayed glial scar formation. However, not all scar characteristics form inhibitory barriers. During the acute to subacute stages, the proliferation of astrocytes is responsible for isolating the injury site to reduce the diffusion of cytotoxic molecules and inflammatory cells to adjacent, undamaged tissue. In addition, astrocytes around the injury may provide local nutritional support and promote angiogenesis [15]. Qi W found that early SCI, after TMP intervention, the number of GFAP-positive cells increased compared to the model group, reaching a peak on day 7 and then gradually decreasing [16]. However, the decrease was smaller than the increase observed before day 7, indicating that TMP promotes the activation of astrocytes during the acute phase to enhance endogenous repair mechanisms. This finding does not contradict the previous study, one of which focused on the increase in GFAP-positive cells during the acute phase, while the other observed a reduction in GFAP-positive cell area during the chronic phase. This suggests that TMP does not simply upregulate or downregulate GFAP expression but exerts “biphasic” regulation on astrocytes, thereby maximizing the potential for neural repair. Promotion of neural stem cell proliferation and differentiation Endogenous neural stem cells (ENSCs), as pluripotent neural stem cells, are located in the central canal region of the spinal cord of adult mammals. They are activated after SCI and then differentiate into various neural cells, promoting endogenous repair and regeneration [17]. Qi W found that after TMP intervention, the number of proliferating cell markers (BrdU+) and the expression of neural stem/progenitor cell markers (Nestin+) were significantly increased, promoting the proliferation and differentiation of endogenous stem cells [18]. (2)Improvement of vascular dysfunction. (2)Improvement of vascular dysfunction. Improvement of vascular dysfunction. Vasodilation to improve blood supply Endothelin is present in various organs and tissues, such as the spinal cord and heart. It is the most potent and long-lasting endogenous vasoconstrictor substance discovered to date, causing vasospasm and exacerbating ischemia after SCI. Thromboxane A2 (TXA2) is a potent bioactive substance synthesized and released by platelet microvesicles, which strongly promotes vasoconstriction and platelet aggregation. Endothelial nitric oxide synthase (eNOS) is primarily found in endothelial cells, and the nitric oxide (NO) it produces can dilate blood vessels and inhibit platelet aggregation and adhesion. Several studies have found that after SCI, TMP intervention significantly reduces the levels of endothelin [19] and thromboxane A2 in the damaged spinal cord tissue of rats, while increasing eNOS expression in the early stages of injury [20]. Inhibition of endothelial cell apoptosis Endothelial cells are an important component of the blood-spinal cord barrier. SCI can lead to endothelial cell apoptosis, further increasing the permeability of the blood-spinal cord barrier and exacerbating secondary damage to the microvasculature [21]. The integrity of the vascular structure is a prerequisite for the normal function of the blood-spinal cord barrier. Li DZ found through experiments that after injecting TMP into rats with SCI, the number of endothelial cell apoptoses at different postoperative time points in the TMP group was lower than in the control group [22]. They suggested that TMP can inhibit endothelial cell apoptosis after acute SCI and simultaneously increase the density of micro vessels. HU found that after injecting TMP into rats with SCI, endothelial cell apoptosis was significantly reduced [23]. Subsequently, using Micro CT scanning, they discovered that the TMP group had better indicators of vascular quantity, vascular volume fraction, and vascular continuity in the spinal cord tissue compared to the control group, thus proving that TMP can promote angiogenesis by inhibiting endothelial cell apoptosis. Additionally, the main components of micro vessels, such as endothelial cells, type IV collagen, laminin, as well as type I collagen and type XVIII collagen, which regulate vascular regeneration, and matrix metalloproteinases (MMPs) like MMP-2 and MMP-9 [24], which have a degrading effect on type IV collagen, all play a leading role in maintaining the integrity of the blood-spinal cord barrier. TMP can reduce the expression of matrix metalloproteinases MMP-2 and MMP-9, promote the expression of type IV collagen, laminin, and type I collagen in the early stages after SCI, as well as enhance the expression of type XVIII collagen [22]. It also inhibits endothelial cell apoptosis, promotes angiogenesis, increases microvascular density, improves vascular morphology, thereby alleviating neural damage. Improvement of hemorheology Hemorheology is the study of the flow properties and changes in blood and its components. It reflects changes in the internal environment of the circulatory system. After SCI, microcirculatory disorders are closely related to changes in hemorheology. Liu G found that on the 7th day after SCI, TMP significantly reduced whole blood viscosity (at low, high, and medium shear rates) and plasma viscosity [25]. On the 14th day, TMP increased the red blood cell deformability index. TMP can improve the hypercoagulable state of blood after SCI, promote the repair of microcirculation, and to some extent, prevent complications such as deep vein thrombosis in the lower limbs after SCI. Promotion of angiogenesis PGC-1 factors are involved in intracellular oxidative metabolism and mitochondrial biogenesis. They can activate estrogen receptor ERR, thereby upregulating vascular endothelial growth factor (VEGF) gene expression and promoting angiogenesis. He ZY found that TMP can upregulate PGC-1α/ERR-α, improving blood circulation after SCI [26]. Zhou Y, through vascular immunofluorescence double labeling and synchrotron micro-CT, observed that TMP can multidimensionally promote vascular repair and improve microcirculation after SCI [27]. In terms of two-dimensional structure, it significantly increases the microvascular density and the number of new blood vessels in the damaged area. In the more detailed three-dimensional structure, it mainly acts on functional micro vessels (diameter < 40 μm), accelerating the remodeling of a more intact microvascular three-dimensional network by increasing total vascular capacity, reducing vascular tortuosity, and enhancing the connectivity of the vascular network. Wu TD also observed that TMP can significantly increase blood flow perfusion in the damaged spinal cord (vascular volume fraction, VVF) [28], dilate micro vessel diameters, promote the recovery of micro vessel numbers, upregulate the expression of VEGF, and promote angiogenesis, thereby enhancing the recovery of microcirculation. (3)Anti-inflammatory. (3)Anti-inflammatory. Anti-inflammatory. The expression of C-reactive protein in the serum of rats after SCI was significantly increased. After the addition of TMP, the expression of C-reactive protein was significantly reduced compared to the model group, indicating that TMP can improve the inflammatory microenvironment in rats with SCI [29]. Regulation of interleukins Interleukins play a significant role in transmitting information, activating and regulating immune cells, mediating T and B lymphocyte activation, and contributing to inflammation. Li XM found that after SCI in rats, the injection of TMP led to an increase in interleukin 10 (IL-10) and a decrease in interleukin 18 (IL-18) expression [30]. TMP can restore neurological function after SCI by inhibiting pro-inflammatory cytokines and promoting the expression of anti-inflammatory factors. Wang C found that TMP can reduce the expression of various pro-inflammatory cytokines (including IL-1β, TNF-α, and IL-18), and these effects can be reversed by the HO-1 inhibitor (ZnPP) and the Akt inhibitor (LY294002) [31]. TMP inhibited the reduction of Akt phosphorylation and increased the expression of Nrf2 in rats after SCI. This inhibitory effect was suppressed by LY294002 but not by ZnPP. Therefore, TMP can improve the inflammatory response after SCI through the Akt/Nrf2/HO-1 pathway. TMP first activates the Akt signaling, which further activates the transcription factor Nrf2. Activated Nrf2 enters the nucleus, binds to the promoter region of the HO-1 gene, and upregulates the expression of HO-1. Abnormal activation of signaling pathways such as STAT3 can promote the secretion of IL-17. Zhang N found that TMP can effectively inhibit the phosphorylation of STAT3 and the expression of IL-17 after SCI [32]. TMP can suppress STAT3 activity, reduce IL-17 levels, and promote spinal cord recovery. High expression of COX-2 catalyzes the production of large amounts of prostaglandins, particularly PGE2. PGE2 is a potent pro-inflammatory factor that further amplifies the inflammatory response. Microglia are the primary immune cells in the central nervous system. After SCI, microglia are rapidly activated. Moderate activation in the early stages after injury helps clear debris, but excessive activation releases large amounts of pro-inflammatory cytokines. Shin JW found that TMP treatment can also reduce COX-2 expression after SCI and attenuate microglial activation at 48 h post-SCI [33]. Additionally, TMP promotes the polarization of microglia from the M1 type to the M2 type, thereby protecting neurons [34]. In addition, the NF-κB pathway is involved in regulating the inflammatory response after SCI. Abnormal activation of NF-κB in neurons and glial cells can upregulate NF-κB-dependent pro-inflammatory cytokines and chemokines, leading to the infiltration of inflammatory cells and exacerbating secondary damage [35]. Liu G found that TMP reduced the protein expression of TNFR1, IκB-α, and NF-κB p65 in spinal cord tissue. The inhibition of the inflammatory response by TMP may be related to the modulation of the TNFR1/IκB-α/NF-κB p65 signaling pathway [36]. Hu JZ and Xiao ZM found that TMP not only regulates the expression of IL-10 and IL-18 after SCI but also promotes the expression of IκB-α, inhibiting the expression of MIF and NF-κB [37]. They suggested that the mechanism by which TMP reduces NF-κB may involve the inhibition of MIF expression, leading to increased expression of IκB-α. Additionally, P2 × 7R is an important member of the purinergic receptor family, triggered by ATP, leading to the release of inflammatory and immune mediators. Fan X found that after TMP treatment, the number of activated microglia (IBA-1+) expressing P2 × 7R (P2 × 7R+/IBA-1 + cells) in spinal cord tissue was significantly reduced [38]. TMP also significantly decreased the expression levels of key proteins in the NLRP3 inflammasome pathway, including NLRP3 and activated Caspase-1, as well as downregulated the levels of pro-inflammatory cytokines IL-1β and IL-18 induced by SCI. Therefore, TMP effectively improves the inflammatory response after SCI by targeting the P2 × 7R/NLRP3 axis. Inhibition of neutrophil infiltration Neutrophils can rapidly infiltrate the injury site within 24 h after SCI, thereby mediating the inflammatory response. Myeloperoxidase is a heme protein, and external stimuli can lead to the accumulation of neutrophils, which in turn release myeloperoxidase. Fan LH found that myeloperoxidase activity in spinal cord tissue significantly increased in response to ischemia-reperfusion injury, while TMP treatment notably reduced myeloperoxidase activity in the injury area and decreased neutrophil infiltration [10]. P-selectin is expressed on the surface of activated endothelial cells and platelets, and it mediates initial cell adhesion, initiating the adhesion and migration cascade of leukocytes, especially neutrophils. Once neutrophils are activated by adhesion, they release neutrophil elastase (NE), which promotes the expression of IL-2 and IL-6, thereby exacerbating the inflammatory response. Li JH found that TMP can inhibit the expression of P-selectin in spinal cord tissue after acute SCI in rats, reduce the levels of neutrophil elastase, and alleviate secondary damage caused by the inflammatory response [39]. (4)Inhibition of neuronal apoptosis. (4)Inhibition of neuronal apoptosis. Inhibition of neuronal apoptosis. Regulation of the caspase family Caspases are Ca²⁺-dependent proteases. After acute SCI, Caspases can induce neuronal apoptosis [40]. Shen ZX found that in SCI rats treated with TMP, the expression of Caspase-3 decreased at all postoperative time points, reaching the lowest value on the 7th day [41]. TMP can inhibit neuronal apoptosis by regulating the expression of Caspase-3. The expression of Fas-associated death domain protein (FADD) activates the caspase cascade to execute apoptosis. Wang SX found that in the TMP injection group, the expression of Caspase-8 and FADD decreased at different postoperative time points [42]. Regulation of the Bcl-2 family The Bcl-2 family is closely associated with cell apoptosis. Bcl-2 protein inhibits apoptosis, while Bax protein antagonizes its effect, forming a positive and negative regulation system for cell apoptosis [43]. Sun HY found that TMP can promote the expression of Bcl-2 and inhibit the expression of Bax after SCI [44]. A significant change in numerous miRNAs was observed in rats after SCI, with miR-214-3p being significantly upregulated. miRNA is a short non-coding RNA, and miR-214-3p is a pro-apoptotic factor in SCI. It directly targets Bcl-2 mRNA, leading to the degradation of Bcl-2 protein, thereby accelerating neuronal apoptosis in the spinal cord. Fan YZ confirmed that TMP inhibits cell apoptosis in vivo by reducing miR-214-3p levels and increasing Bcl2l2 expression [45]. Wang G found that TMP can upregulate the expression of miRNA-24 in spinal cord tissue after SCI in rats, while simultaneously downregulating the expression of the pro-apoptotic Bim protein in the Bcl-2 family [46]. Huang JH found that TMP can inhibit neuronal apoptosis by increasing the expression of miRNA-21 and decreasing the expression of pro-apoptotic genes such as FasL, PTEN, and PDCD4 [47]. In addition, Sun HY also found that TMP reduces neuronal apoptosis and inhibits the occurrence of secondary damage by suppressing the expression of the pro-apoptotic gene c-fos after SCI [48]. (5) Antioxidant stress (5) Antioxidant stress Antioxidant stress Malondialdehyde (MDA) is the end product of lipid peroxidation and is cytotoxic. Superoxide dismutase (SOD) is an endogenous antioxidant that acts to protect cells. Pu QL found that TMP can increase the SOD activity in spinal cord tissue and inhibit the generation of MDA, showing significant antioxidant damage protection [49]. The Nrf2 pathway is involved in regulating oxidative stress injury, and its downstream molecule HO-1 can degrade heme and exert antioxidant effects by regulating free iron metabolism. Under physiological conditions, Nrf2 binds with Keap1 to form the Nrf2-Keap1 dimer. In the case of redox imbalance, the Keap1 dimer is competitively bound by P62, which disrupts the binding with Nrf2 and releases its transcriptional function. Tao JW found that in the TMP group, the expression levels of Nrf2, HO-1, and P62 in spinal cord tissue were higher than those in the model group, while the expression of Keap1 was significantly lower than that in the model group [50]. Additionally, ROS expression was lower in the TMP group compared to the model group. These findings preliminarily demonstrate that TMP can exert neuroprotective effects by regulating antioxidant activity through the Nrf2/HO-1 signaling pathway. In addition, Liu G found that TMP inhibits oxidative stress after SCI, which may also be related to the regulation of the TNFR1/IκB-α/NF-κB p65 signaling pathway [36]. Huo LY found that the decrease in PKD1 gene expression after SCI is associated with significant oxidative stress, and TMP effectively reversed this response [3]. (6) Improvement of iron metabolism (6) Improvement of iron metabolism Improvement of iron metabolism After SCI, ruptured red blood cells release a large amount of free iron ions (Fe²⁺ and Fe³⁺), which accumulate at the injury site, causing local iron metabolism disorders, known as iron overload. Through the Fenton reaction, a large amount of reactive oxygen species is generated, inducing ferroptosis in neuronal cells. Regulating iron metabolism disorders is of great significance for SCI repair [51]. Fan X found that after TMP intervention, the expression of FTH1 and FTL proteins was promoted following SCI [52]. It is known that FTH1 and FTL can bind free iron ions to form ferritin, thereby reducing the content of free iron ions and regulating iron metabolism [53], therefore, the average absorbance value of Prussian blue staining in spinal cord tissue was significantly reduced compared to the model group, indicating that TMP can reduce iron deposition. After SCI, local iron overload and stress can activate a series of lipid peroxidation reactions, both of which can induce ferroptosis following SCI [54]. GPX4 is a cysteine-containing, glutathione-dependent enzyme and a key regulator of ferroptosis. It converts glutathione into oxidized glutathione, thereby reducing lipid peroxidation and oxidative stress damage [55]. Tao JW found that in the TMP group, compared to the model group, the protein expression levels of GPX4, ferritin heavy chain, and iron export proteins in spinal cord tissue were increased [56]. At the same time, glutathione and SOD levels were elevated, and MDA levels were reduced. Additionally, the expression of neuron-specific nuclear protein in spinal cord tissue was increased. Based on this, it is inferred that TMP can exert neuroprotective effects by regulating lipid peroxidation and iron metabolism to inhibit neuronal ferroptosis. ACSL4 is a key isomerase that can convert polyunsaturated fatty acids into unsaturated fatty acid phospholipids, thereby increasing the cell’s sensitivity to ferroptosis [57]. Liu G found that TMP improved the microstructure of mitochondria, reduced the levels of ROS, GSH, MDA, and SOD, increased GPX4 levels, and simultaneously reduced ACSL4 levels and inhibited glial scar formation. Additionally, the effects of TMP could be reversed by using RSL3, a GPX4 inhibitor [58]. These findings suggest that TMP may alleviate ferroptosis and lipid peroxidation through the GPX4/ACSL4 axis. The transcription factor NRF2, which is the nuclear factor of NFE2L2, regulates the transcription of most ferroptosis-related genes by binding to antioxidant response elements [59]. Tao JW found that compared to the model group, the TMP group showed increased expression of NRF2, and the levels of iron metabolism-related molecules FTH1, FTL, and FPN1 were higher in the TMP group. This preliminary evidence suggests that TMP regulates iron metabolism and the NRF2/ARE pathway [60]. (7) Regulation of ion homeostasis (7) Regulation of ion homeostasis Regulation of ion homeostasis Antagonism of calcium ion influx After SCI, the imbalance of ion homeostasis involves various ion abnormalities and cellular dysfunctions, such as calcium overload, potassium efflux, and sodium influx. Particularly, calcium ions are critical, as the significant increase in cytoplasmic Ca²⁺ exacerbates vasospasm and ischemia, damages mitochondrial function, and acts as an essential cofactor promoting cell necrosis and apoptosis [61]. Li GH found that after TMP treatment, the activity of spinal cord mitochondrial PLA2 and the concentration of MDA were reduced, while the activity of SOD and Ca²⁺-Mg²⁺-ATPase was increased [62]. TMP antagonized calcium ion influx and alleviated oxidative stress-mediated damage to mitochondrial membrane structure and function. Sun HY found that after injecting TMP into rats with SCI, the levels of Ca²⁺ and water content in the spinal cord tissue were reduced, alleviating electrolyte imbalance in the injured spinal cord area and preventing a series of pathological responses caused by intracellular calcium overload [63]. Inhibition of potassium ion efflux Li H found that TMP can inhibit the outward delayed rectifier potassium current in the anterior horn motor neurons of rats with complete spinal cord transection, stabilize the membrane potential, and protect spinal cord neurons [64]. (8) Anti-pyroptosis (8) Anti-pyroptosis Anti-pyroptosis Pyroptosis is a form of programmed cell death, primarily characterized by inflammasome formation, caspase and GSDMD activation, and the extensive release of pro-inflammatory cytokines. This process disrupts cellular integrity and exacerbates the inflammatory response [65]. Tao B found that TMP intervention could downregulate the protein expression of NLRP3, ASC, Caspase-1, and GSDMD in the pyroptosis pathway following spinal cord injury (SCI). Additionally, TMP was shown to suppress NLRP3 inflammasome-mediated pyroptosis by inhibiting the NF-κB signaling pathway [34]. (9) Regulation of autophagy (9) Regulation of autophagy Regulation of autophagy Autophagy is a crucial defense mechanism that maintains cellular metabolism and homeostasis by eliminating protein aggregates and damaged organelles. By activating autophagy, cell death can be inhibited, offering neuroprotective effects in SCI [66]. Macrophages, key components of the immune system, can phagocytose damaged tissue debris and pathogens, regulate inflammation, and assist in tissue repair. Song XM observed that TMP intervention increased both the number of autophagosomes and the expression level of LC3Ⅱ protein in spinal cord macrophages following damage [67]. Therefore, TMP may effectively repair SCI in rats, with its molecular mechanism likely linked to the activation of autophagy in spinal cord macrophages. TMP demonstrates powerful potential in treating SCI, highlighting its multifaceted and multi-target characteristics. It exerts its effects through various pathways at the cellular and molecular levels, including antioxidant, anti-apoptotic, and anti-inflammatory pathways. TMP also exhibits network-based regulation, enabling precise intervention at key molecular or pathway hubs within the pathological network of SCI. This allows for the effective modulation of multiple interconnected pathological and physiological processes, resulting in synergistic therapy and comprehensive repair. For instance, TMP inhibits apoptosis, promotes angiogenesis, and supports neural regeneration and repair by decreasing miR-497-5p expression while increasing EGFL7 expression [68];Furthermore, TMP reduces inflammation, oxidative stress, and other responses following SCI by downregulating the NF-κB pathway. Detailed in vivo experimental data can be found in Table 2. The relevant pathways for the in vivo effects of TMP are illustrated in Fig. 4. Table 2In vivo experiments of TMP in SCI repairAnimalDiseaseInterventionNumber of animalsTreatmentdurationResultsCaseControlCaseControlhuang2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)10105d① BBB score, Inclined Plane TestSu2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS303014d① BBB score, Jacobs score ② Histomorphology of the Spinal CordSun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS885d① BBB score, Inclined Plane Test ② Histomorphology of the Spinal Cordkuang2011SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15155d① MEPWang2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)DANSHEN (200 mg/kg)101010d① BBB score ②MEPWang2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (10 g/L 5 ml)Gal (0.0025 g/L 5 ml)202028d① MEPZhao2013SD RatSCI (Allen’s weight dropSCI trauma method)TMP (200 mg/kg)NS323212d① Inclined Plane Test ②TUNEL StainingQi2011Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP(50 ml/d)NS303014d① BBB score②NOS、IL-1βshen2008SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d① BBB score, Inclined Plane Test ② Histomorphology of the Spinal Cord ③ caspase-4,NF-L, NF-H, NF-Mhuang2014SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS28283d① BBB score ② Histomorphology of the Spinal Cord③miR-21④ TUNEL Staining ⑤ FasL, PTEN, PDCD4pu2017Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30307d① SOD, MDAsong2025SD RatSCI (Allen’s weight drop SCI trauma method)TMP (150,200 mg/kg)NS201028d① BBB score ② Histomorphology of the Spinal Cord ③ SOD, MDA ④ TUNEL Staining ⑤ LC3Ⅰ, LC3Ⅱ, Bax, Bcl-2sun2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS6060ONCE① Bcl-2, baxsun2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS4848ONCE① Histomorphology of the Spinal Cord ② TXB2, 6-Keto-PGF1α, MDAsun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3030ONCE① C-fostao2025Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30307d① BBB score, Inclined Plane Test ② MEP ③ Histomorphology of the Spinal Cord ④ MRI ⑤ CD 86, CD 206, IL-1β, IL-10tao2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (100,150,200 mg/kg)NS361228d① BBB score ② Nissl Staining ③ SOD, MDA ④ Nrf2, HO-1 ⑤ ROSwang2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS36365d① miRNA-24, Bim ② Tunel Stainingwang2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30302d① BBB score ② Caspase-3wang2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS45455d① BBB score, Inclined Plane Test, CBS score ② FADD ③ Caspase-8yan2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30302d① BBB scoreyuan2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (40 mg/kg)NS48485d① Inclined Plane Test,Tarlov score ② TUNEL Staining, Hoechst Stainingzhang2022SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS12125d① BBB score, Inclined Plane Test ② Nissl Staining ③ CRP ④ NF-κB,TNF-α, IL-10zhao2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363612d①Histomorphology of the Spinal Cord②Caspase-3③TUNEL Stainingzhao2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363614d①Histomorphology of the Spinal Cordhu2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS60605d①BBB score②TUNEL, Nissl Staining③PGC-1αhuang2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS32323d①BBB score②Cresyl Violet Staining③miR-21④FasL, PDCD4, PTEN⑤TUNEL Stainingfan2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS5514d①BBB score②miR-214-3p、Bcl2l2、Bax、caspase 3③TUNEL Stainingzeng2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS101014d①BBB score②miR-497-5p、EGFL7③Histomorphology of the Spinal Cord④CD31 ⑤TNF-α、TGF-β、IL-1βhuo2025SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS23237d①BBB score②CatWalk③MEP④Histomorphology of the Spinal Cord⑤NeuN、PKD1⑥ROSliu2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15157d①BBB score② Histomorphology of the Spinal Cord③TNF-α、IL-1β、ROS、SOD、MDA④TNFR1、IκBα、p-IκBα、NFκB p65、p-NFκB p65qi2024C57BL/6 miceSCI (Allen’s weight drop SCI trauma method)TMP (25,50,100 mg/kg)NS451514d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③RAS、RAF1、ERK1/2、PI3K、p-AKTliu2023SD RatFull Transection SCITMP (200 mg/kg)NS18185d①Hemorrheological Parameterssun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3232ONCE①Ca2+、K+、Na+li2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS1010ONCE①SOD、PLA2、MDA、Ca²⁺-Mg²⁺-ATPaseli2009SD RatFull Transection Spinal Cord InjuryTMP (8 mM)NS1210ONCE①K+li2005dogSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)FK (60 mg/kg)12127d①Behavioral Score②MRI③Histomorphology of the Spinal Cord④MBP、S-100B ⑤NF 、GFAPchen2004dogSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)NS1267d①BBB score②MRI③Histomorphology of the Spinal Cord④NF、GFAPwang2001RabbitSpinal Cord Ischemia InjuryTMP (15,30,60 mg/kg)NS2062d①Histomorphology of the Spinal Cordchen2002RabbitSpinal Cord Ischemia InjuryTMP (15,30,60 mg/kg)NS248ONCE①MFS score②Histomorphology of the Spinal Cordfan2006RabbitSpinal Cord Ischemia InjuryTMP (200 mg/kg)NS1212ONCE①Johnson score②Histomorphology of the Spinal Cord③SOD、MDA④Bcl-2、Bax⑤TUNEL Stainingtao2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15157d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③ROSliu2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3697d①BBB score②Histomorphology of the Spinal Cord③GPX4、Fe、ROS、GSH、MDA、SOD④NeuN、GFAP、GPX4、ACSL4tao2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS121228d①BBB score②Histomorphology of the Spinal Cord③GSH、SOD、MDA④GPX4fan2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS121228d①BBB score②Histomorphology of the Spinal Cord③Fe④WB、FTH1、FPN1zhou2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score②NGF、BDNyang2020SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score、Inclined Plane Test②NT-4、TrkAxiong2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363610d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③Brdu+、Nestin+、GFAPwang2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30305d①BBB score②Histomorphology of the Spinal Cord③GAP-43qi2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (400 mg/kg)MP (30 mg/kg)363610d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③Brdu+、Nestin+④Ihh、Glilqi2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363610d①Brdu+、Nestin+、GFAP+chen2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS39395d①BBB score②Histomorphology of the Spinal Cord③GFAP、cPLA2he2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS24245d①Histomorphology of the Spinal Cord②PGC-1α、ERR-αhuang2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (32 mg/kg)NS887d①CBS score②Histomorphology of the Spinal Cord③iNOs④TXB2⑤ETli2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30305d①Histomorphology of the Spinal Cord②Col IV、LN、Col I、Col XVIII③MMP-2、MMP-9li2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score、Inclined Plane Test②Hemorrheological Parameters③EThu2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS10105d①BBB score②MMP2、MMP-9、Bax、caspase-3③TUNEL Staining④SRµCThu2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS555d①BBB score②CT③PCNA/RECA-1wu2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①Histomorphology of the Spinal Cord②VEGF、HIF-1αzhou2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS24245d①Histomorphology of the Spinal Cordfan2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30304d①BBB score②Nissl and Golgi Staining③IL-1、IL-18④P2 × 7R+/IBA-1+⑤P2 × 7R ⑥NLRP3、Cleaved-Caspase-1(p20)li2020SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS45455d①BBB score、Inclined Plane Test、CBS scoreli2023C57BL/6miceSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS451514d①BBB score, Inclined Plane Test②TNF-α, IL-6、IL-1β③Histomorphology of the Spinal Cord④GFAP, C3li2008SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①BBB score, Inclined Plane Test②IL-10, IL-18fan2011SD RatSpinal Cord Ischemia InjuryTMP (30 mg/kg)NS3030once①BBB score②TTC Staining③Nissl Staining④IL-1β, TNF-α, IL-10, NF-κβ(p65)⑤MPOhu2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①BBB score②MIF, NF-κβ, IL-18shin2013C57BL/6 miceSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)NS2010once①TNF-α, IL-1β, COX-2②Inoswang2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS10105d①BBB score②TUNEL Staining, caspase 3③IL-1β, TNFα, IL-18④Nrf2, HO-1, Aktxiao2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS50505d①BBB score, Inclined Plane Test, CBS score②MIF, NF-KB, I-KBαzhang2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (40 mg/kg)NS20207d①BBB score②Histomorphology of the Spinal Cord③IL-17, STAT3 Table 2In vivo experiments of TMP in SCI repairAnimalDiseaseInterventionNumber of animalsTreatmentdurationResultsCaseControlCaseControlhuang2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)10105d① BBB score, Inclined Plane TestSu2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS303014d① BBB score, Jacobs score ② Histomorphology of the Spinal CordSun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS885d① BBB score, Inclined Plane Test ② Histomorphology of the Spinal Cordkuang2011SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15155d① MEPWang2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)DANSHEN (200 mg/kg)101010d① BBB score ②MEPWang2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (10 g/L 5 ml)Gal (0.0025 g/L 5 ml)202028d① MEPZhao2013SD RatSCI (Allen’s weight dropSCI trauma method)TMP (200 mg/kg)NS323212d① Inclined Plane Test ②TUNEL StainingQi2011Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP(50 ml/d)NS303014d① BBB score②NOS、IL-1βshen2008SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d① BBB score, Inclined Plane Test ② Histomorphology of the Spinal Cord ③ caspase-4,NF-L, NF-H, NF-Mhuang2014SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS28283d① BBB score ② Histomorphology of the Spinal Cord③miR-21④ TUNEL Staining ⑤ FasL, PTEN, PDCD4pu2017Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30307d① SOD, MDAsong2025SD RatSCI (Allen’s weight drop SCI trauma method)TMP (150,200 mg/kg)NS201028d① BBB score ② Histomorphology of the Spinal Cord ③ SOD, MDA ④ TUNEL Staining ⑤ LC3Ⅰ, LC3Ⅱ, Bax, Bcl-2sun2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS6060ONCE① Bcl-2, baxsun2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS4848ONCE① Histomorphology of the Spinal Cord ② TXB2, 6-Keto-PGF1α, MDAsun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3030ONCE① C-fostao2025Wistar RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30307d① BBB score, Inclined Plane Test ② MEP ③ Histomorphology of the Spinal Cord ④ MRI ⑤ CD 86, CD 206, IL-1β, IL-10tao2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (100,150,200 mg/kg)NS361228d① BBB score ② Nissl Staining ③ SOD, MDA ④ Nrf2, HO-1 ⑤ ROSwang2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS36365d① miRNA-24, Bim ② Tunel Stainingwang2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30302d① BBB score ② Caspase-3wang2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS45455d① BBB score, Inclined Plane Test, CBS score ② FADD ③ Caspase-8yan2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30302d① BBB scoreyuan2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (40 mg/kg)NS48485d① Inclined Plane Test,Tarlov score ② TUNEL Staining, Hoechst Stainingzhang2022SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS12125d① BBB score, Inclined Plane Test ② Nissl Staining ③ CRP ④ NF-κB,TNF-α, IL-10zhao2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363612d①Histomorphology of the Spinal Cord②Caspase-3③TUNEL Stainingzhao2006SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363614d①Histomorphology of the Spinal Cordhu2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS60605d①BBB score②TUNEL, Nissl Staining③PGC-1αhuang2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS32323d①BBB score②Cresyl Violet Staining③miR-21④FasL, PDCD4, PTEN⑤TUNEL Stainingfan2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS5514d①BBB score②miR-214-3p、Bcl2l2、Bax、caspase 3③TUNEL Stainingzeng2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS101014d①BBB score②miR-497-5p、EGFL7③Histomorphology of the Spinal Cord④CD31 ⑤TNF-α、TGF-β、IL-1βhuo2025SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS23237d①BBB score②CatWalk③MEP④Histomorphology of the Spinal Cord⑤NeuN、PKD1⑥ROSliu2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15157d①BBB score② Histomorphology of the Spinal Cord③TNF-α、IL-1β、ROS、SOD、MDA④TNFR1、IκBα、p-IκBα、NFκB p65、p-NFκB p65qi2024C57BL/6 miceSCI (Allen’s weight drop SCI trauma method)TMP (25,50,100 mg/kg)NS451514d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③RAS、RAF1、ERK1/2、PI3K、p-AKTliu2023SD RatFull Transection SCITMP (200 mg/kg)NS18185d①Hemorrheological Parameterssun2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3232ONCE①Ca2+、K+、Na+li2005SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS1010ONCE①SOD、PLA2、MDA、Ca²⁺-Mg²⁺-ATPaseli2009SD RatFull Transection Spinal Cord InjuryTMP (8 mM)NS1210ONCE①K+li2005dogSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)FK (60 mg/kg)12127d①Behavioral Score②MRI③Histomorphology of the Spinal Cord④MBP、S-100B ⑤NF 、GFAPchen2004dogSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)NS1267d①BBB score②MRI③Histomorphology of the Spinal Cord④NF、GFAPwang2001RabbitSpinal Cord Ischemia InjuryTMP (15,30,60 mg/kg)NS2062d①Histomorphology of the Spinal Cordchen2002RabbitSpinal Cord Ischemia InjuryTMP (15,30,60 mg/kg)NS248ONCE①MFS score②Histomorphology of the Spinal Cordfan2006RabbitSpinal Cord Ischemia InjuryTMP (200 mg/kg)NS1212ONCE①Johnson score②Histomorphology of the Spinal Cord③SOD、MDA④Bcl-2、Bax⑤TUNEL Stainingtao2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS15157d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③ROSliu2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS3697d①BBB score②Histomorphology of the Spinal Cord③GPX4、Fe、ROS、GSH、MDA、SOD④NeuN、GFAP、GPX4、ACSL4tao2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS121228d①BBB score②Histomorphology of the Spinal Cord③GSH、SOD、MDA④GPX4fan2023SD RatSCI (Allen’s weight drop SCI trauma method)TMP (80 mg/kg)NS121228d①BBB score②Histomorphology of the Spinal Cord③Fe④WB、FTH1、FPN1zhou2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score②NGF、BDNyang2020SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score、Inclined Plane Test②NT-4、TrkAxiong2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363610d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③Brdu+、Nestin+、GFAPwang2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30305d①BBB score②Histomorphology of the Spinal Cord③GAP-43qi2013SD RatSCI (Allen’s weight drop SCI trauma method)TMP (400 mg/kg)MP (30 mg/kg)363610d①BBB score、Inclined Plane Test②Histomorphology of the Spinal Cord③Brdu+、Nestin+④Ihh、Glilqi2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS363610d①Brdu+、Nestin+、GFAP+chen2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS39395d①BBB score②Histomorphology of the Spinal Cord③GFAP、cPLA2he2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS24245d①Histomorphology of the Spinal Cord②PGC-1α、ERR-αhuang2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (32 mg/kg)NS887d①CBS score②Histomorphology of the Spinal Cord③iNOs④TXB2⑤ETli2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS30305d①Histomorphology of the Spinal Cord②Col IV、LN、Col I、Col XVIII③MMP-2、MMP-9li2007SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS25255d①BBB score、Inclined Plane Test②Hemorrheological Parameters③EThu2017SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS10105d①BBB score②MMP2、MMP-9、Bax、caspase-3③TUNEL Staining④SRµCThu2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS555d①BBB score②CT③PCNA/RECA-1wu2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①Histomorphology of the Spinal Cord②VEGF、HIF-1αzhou2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS24245d①Histomorphology of the Spinal Cordfan2024SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)MP (30 mg/kg)30304d①BBB score②Nissl and Golgi Staining③IL-1、IL-18④P2 × 7R+/IBA-1+⑤P2 × 7R ⑥NLRP3、Cleaved-Caspase-1(p20)li2020SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS45455d①BBB score、Inclined Plane Test、CBS scoreli2023C57BL/6miceSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS451514d①BBB score, Inclined Plane Test②TNF-α, IL-6、IL-1β③Histomorphology of the Spinal Cord④GFAP, C3li2008SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①BBB score, Inclined Plane Test②IL-10, IL-18fan2011SD RatSpinal Cord Ischemia InjuryTMP (30 mg/kg)NS3030once①BBB score②TTC Staining③Nissl Staining④IL-1β, TNF-α, IL-10, NF-κβ(p65)⑤MPOhu2012SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS40405d①BBB score②MIF, NF-κβ, IL-18shin2013C57BL/6 miceSCI (Allen’s weight drop SCI trauma method)TMP (15,30 mg/kg)NS2010once①TNF-α, IL-1β, COX-2②Inoswang2016SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS10105d①BBB score②TUNEL Staining, caspase 3③IL-1β, TNFα, IL-18④Nrf2, HO-1, Aktxiao2010SD RatSCI (Allen’s weight drop SCI trauma method)TMP (200 mg/kg)NS50505d①BBB score, Inclined Plane Test, CBS score②MIF, NF-KB, I-KBαzhang2015SD RatSCI (Allen’s weight drop SCI trauma method)TMP (40 mg/kg)NS20207d①BBB score②Histomorphology of the Spinal Cord③IL-17, STAT3 In vivo experiments of TMP in SCI repair Fig. 4Signal Pathways Involved in the Pathophysiological Process of SCI by TMP.(The image was created using Photoshop) Signal Pathways Involved in the Pathophysiological Process of SCI by TMP.(The image was created using Photoshop) ①TNFR1/IκB-α/NF-κB p65 signaling pathway②Akt/Nrf2/HO-1 signaling pathway③NRF2/ARE signaling pathway④GPX4/ACSL4 signaling pathway⑤PGC-1α/ERR-αsignaling pathway⑥HIF-1α/VEGF signaling pathway⑦P2 × 7R/NLRP3 signaling pathway. The above describes the molecular-level changes of TMP in the intervention of SCI. The therapeutic effects of TMP are reflected in the following improvements in tissue structure and function: Improvement of spinal cord morphology. Improvement of spinal cord morphology. Improvement of spinal cord morphology. TMP promotes the repair of damaged spinal cord tissue. Hematoxylin and eosin (HE) staining revealed that the spinal cord structure in normal rats was intact, with well-preserved anterior horn motor neuron structures and neuronal cell morphology. Following SCI, significant tissue damage was observed, including cavities in the spinal cord, loss of the anterior horn motor neurons, localized cavitation, and infiltration of fibrous connective tissue. However, after TMP intervention, the damage area was markedly reduced, and the survival rate of anterior horn motor neurons improved significantly [60]. (2)Electrophysiological Improvement. (2)Electrophysiological Improvement. Electrophysiological Improvement. TMP also facilitates the functional recovery of damaged spinal cord tissue. Neurophysiological tests, including sensory evoked potentials (SEP) and motor evoked potentials (MEP), were conducted. MEP is particularly useful for evaluating the sensory conduction function of the spinal cord’s dorsal column and for assessing the integrity of the motor pathway from the cortex to the muscles. It serves as a valuable marker for neurological recovery following SCI. In the TMP-treated group, both SEP and MEP showed significantly reduced latency and increased amplitude compared to the injury group, indicating that TMP intervention effectively promotes the recovery of both ascending and descending conduction pathways. This, in turn, aids in the restoration of sensory and motor functions in the spinal cord [34]. (3)Behavioral motor function recovery. (3)Behavioral motor function recovery. Behavioral motor function recovery. Motor function recovery was evaluated using the Basso, Beattie, and Bresnahan (BBB) score and the inclined plane test. After TMP intervention, rats demonstrated significant improvement in the BBB score and a higher inclined plane angle compared to the model group [69]. In summary, TMP facilitates SCI repair and functional recovery by improving spinal cord tissue structure, restoring neurophysiological conduction, and enhancing motor behavioral performance. These effects work synergistically to promote recovery on multiple levels. Other species (dogs, rabbits) Two studies used Chinese native dogs as experimental animals. Both studies established the spinal cord injury model using Allen’s weight-drop method [70, 71]. TMP was administered through an arterial catheter. After treatment, TMP increased the protein levels of MBP, S-100B, NF, and GFAP. It also promoted myelin regeneration, preserved neuronal structural integrity, strengthened the cytoskeleton, and exerted neuroprotective effects. These effects contributed to the recovery of hindlimb motor function and spinal cord morphology in dogs. Three studies used male New Zealand rabbits as experimental animals. All three studies established spinal cord ischemia models using infrarenal aortic occlusion [72–74]. TMP was administered intravenously. After treatment, TMP increased Bcl-2 expression, reduced Bax expression, and decreased the rate of neuronal apoptosis. It also reduced MDA levels and enhanced SOD activity. These effects effectively alleviated oxidative damage in the spinal cord and contributed to neuroprotection. In vitro studies of TMP in SCI A total of five in vitro studies further confirmed the pharmacological effects of TMP. These effects include anti-inflammatory and anti-apoptotic activities, attenuation of oxidative stress, and regulation of iron metabolism. These findings further support the multi-target and multi-pathway synergistic properties of TMP. Zeng TH found that TMP reduced neuronal apoptosis in a dose-dependent manner. TMP also decreased the levels of TGF-β1, TNF-α, and IL-1β. The strongest protective effect was observed at the highest tested concentration, 150 µg/mL [68]. Tao B found that TMP promoted the polarization of LPS-induced BV2 cells from the M1 phenotype toward the M2 phenotype. TMP also downregulated the ASC/NLRP3/Caspase-1/GSDMD signaling axis and inhibited pyroptosis. This resulted in reduced expression of IL-1β and IL-18, indicating marked anti-inflammatory activity [34]. Fan Y found that TMP inhibited MSG-induced neuronal apoptosis. TMP downregulated the expression of the pro-apoptotic proteins caspase-3 and Bax, while upregulating the expression of the anti-apoptotic proteins pro-caspase-3 and Bcl2l2. TMP also counteracted the pro-apoptotic effects induced by miR-214-3p overexpression [45]. Huo LY found that TMP upregulated PKD1 expression, alleviated oxidative stress-induced cellular injury, and increased HO-1 and SOD1 expression [3]. These effects significantly improved cell viability. Tao JW found that TMP enhanced cell viability in a ferroptosis cell model. TMP promoted the expression of iron metabolism-related markers, including FPN1, FTH1, and FTL. It also increased the expression of anti-lipid peroxidation markers, including GPX4 and HO-1, in ferroptotic cells [60]. However, these effects were reversed when Nrf2 expression was downregulated. These findings suggest that TMP regulates iron metabolism through the Nrf2/ARE pathway by promoting the binding of Nrf2 to ARE promoter sequences. Clinical translational research of TMP Substantial progress has been made in translating basic research on traditional Chinese medicine (TCM) into clinically applicable therapies. One promising strategy is to incorporate active monomeric compounds derived from TCM into tissue-engineered biomaterials, such as hydrogels, to enable localized drug delivery at injury sites. This approach improves drug-delivery efficiency and therapeutic efficacy. It also promotes the development of novel treatment strategies and biomaterials. (1)Nanotechnology: TMP has several limitations, including a short half-life, poor water solubility, and low bioavailability. Conventional TMP formulations include tablets, oral drops, and injections. However, these formulations have limited ability to target the spinal cord, which restricts their clinical application in SCI. Nanotechnology provides a promising strategy to overcome these limitations. Zhong ZR conjugated the cell-penetrating HIV transactivator of transcription (TAT) peptide to human serum albumin nanoparticles (NPs) to construct a TMP delivery system, termed TAT-TMP-NPs [75, 76]. This system can be internalized by neutrophils and subsequently targeted to SCI lesions. The encapsulated TMP exhibits sustained-release properties, which may prolong its therapeutic duration in vivo. In rat models of SCI, TAT-TMP-NPs reduced inflammatory cytokine levels and oxidative stress-related markers. They also promoted motor functional recovery without apparent systemic toxicity. (2)Hydrogel: Hydrogels have been widely applied in SCI because of their three-dimensional network structure, spinal cord-like mechanical properties, and ability to conform to the shape and size of the lesion [77]. Hydrogels can bridge injured areas and serve as carriers for various repair-promoting factors. The incorporation of conductive materials can modulate the membrane potential of neural cells. It can also help restore injury-disrupted conductive pathways and maintain the electrical microenvironment required for nerve regeneration [78]. Jiang SY implanted a conductive hydrogel loaded with sustained-release TMP microparticles, termed the “TGTP hydrogel,” into the lesion site of rats with complete spinal cord transection. This treatment improved neurological function, inhibited inflammatory responses, and alleviated structural damage in spinal cord tissue [79]. Wu YP used injectable conductive hydrogel-based tissue-engineering materials to prepare a TMP-loaded supramolecular conductive hydrogel [80]. This hydrogel can be delivered into the injured spinal cord by non-invasive or minimally invasive injection. It is suitable for filling irregular SCI lesions and enables long-term drug delivery at the injury site. It also improves local ischemia and hypoxia, reduces inflammatory responses, and shows substantial potential for clinical translation. Deng BW further optimized this hydrogel by constructing a TMP-loaded conductive hydrogel, referred to as “TGTP,” using gelatin methacryloyl (GelMA) and polypyrrole (Ppy) particles [81, 82]. By mimicking the extracellular matrix, this hydrogel effectively promotes the recruitment of endogenous neural stem cells. It also induces cell adhesion and migration, enhances revascularization in the injured area, and facilitates repair of the blood-spinal cord barrier. This hydrogel exhibits favorable physicochemical properties, biocompatibility, and sustained drug-release performance. Tao JE designed a novel injectable conductive hydrogel composed of water-soluble polypyrrole and agar [83]. This hydrogel can be injected in situ into the injured spinal cord through a non-invasive or minimally invasive approach. Thus, it may enable timely injectable treatment for patients with SCI. In addition, the hydrogel can inhibit ferroptosis by regulating YAP-mediated NCOA4-dependent ferritinophagy, thereby promoting SCI repair. Liu G developed a polyvinyl alcohol (PVA) hydrogel with an oriented porous structure, termed TMP/OPH, by combining sol-gel transition with freeze-forming methods [84]. This strategy enables physical gelation of PVA without additional crosslinking agents. It provides a simple and safe preparation method. Moreover, the gel can revert to a sol state upon heating, indicating potential for environmentally friendly recyclability. Conclusion This review integrates 86 studies demonstrating that tetramethylpyrazine (TMP) has multi-target and multi-pathway therapeutic potential in the treatment of spinal cord injury (SCI). TMP promotes morphological recovery of spinal cord tissue, significantly improves electrophysiological parameters, and enhances motor function scores. The most consistently supported mechanisms include antioxidant stress mediated by the Nrf2/HO-1 pathway, anti-inflammatory effects via the NF-κB pathway, anti-apoptosis regulation by Bcl-2/Bax, and inhibition of ferroptosis through GPX4/ACSL4. Additionally, TMP shows potential in promoting vascular repair, enhancing nerve regeneration, improving ion homeostasis, activating autophagy, and inhibiting pyroptosis, although current evidence in these areas remains limited. However, there are currently few clinical trials, with only three providing evidence for TMP’s therapeutic potential in SCI patients. Moreover, the therapeutic effect of TMP is weaker than that of conventional drugs, such as methylprednisolone [49]. More clinical studies are needed to determine its exact mechanism of action, efficacy, optimal dosage, appropriate administration routes, indications, and potential long-term adverse effects. In conclusion, we believe that TMP could become a viable treatment option for SCI, with the greatest potential as an adjunctive therapy to conventional drugs.